FDA Issues Plausible Mechanism Pathway Draft Guidance

Abstract

Get full access to this article

View all access options for this article.

References

U.S. Food and Drug Administration. Considerations for the use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause: Draft Guidance for Industry. 2026. Available from: https://www.fda.gov/media/191247/download [Last accessed: March 2, 2026].

Davies

. FDA Issues Plausible Mechanism Pathway Draft Guidance to Spur Innovation for Individualized Therapies. Inside Precision Medicine, 2026. Available from: https://www.insideprecisionmedicine.com/topics/molecular-dx/fda-issues-plausible-mechanism-pathway-draft-guidance-to-spur-innovation-for-individualized-therapies/ [Last accessed: March 2, 2026].

Davies

, Philippidis

. Cell and Gene Therapy Leaders Tell FDA: “Believe in American Solutions”. Genetic Engineering & Biotechnology News, 2025. Available from: https://www.genengnews.com/gen-edge/cell-and-gene-therapy-leaders-tell-fda-believe-in-american-solutions/ [Last accessed: March 2, 2026].

U.S. Court of Appeals for the Federal Circuit. Decision, REGENXBIO Inc., Trustees of the University of Pennsylvania, Plaintiffs-Appellants v. Sarepta Therapeutics, Inc., Sarepta Therapeutics Three LLC, Defendants-Appellees. Case: 2024-1408. 2026. Available from: https://www.cafc.uscourts.gov/opinions-orders/24-1408.OPINION.2-20-2026_2650255.pdf [Last accessed: March 3, 2026].

BioMarin Pharmaceutical. BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results. 2026. Available from: https://www.biomarin.com/news/press-releases/biomarin-reports-fourth-quarter-and-full-year-2025-financial-and-operating-results/ [Last accessed: March 2, 2026].

Becker

. BioMarin resigned to ending journey with hemophilia A gene therapy Roctavian, seeks divestiture amid sales struggle. FiercePharma; 2025. Available from: https://www.fiercepharma.com/pharma/biomarin-resigned-ending-journey-hemophilia-gene-therapy-roctavian-seeking-divestiture-amid [Last accessed: March 2, 2026].

uniQure. uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease. 2026. Available from: https://uniqure.gcs-web.com/node/12511/pdf [Last accessed: March 2, 2026].

Prime Medicine. Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates. 2026. Available from: https://investors.primemedicine.com/news-releases/news-release-details/prime-medicine-reports-full-year-2025-financial-results-and [Last accessed: March 2, 2026].

Gori

, Haddad

, Frangoul

, et al. Prime Editing for p47^phox-Deficient Chronic Granulomatous Disease. N Engl J Med, 2025; doi: 10.1056/NEJMoa2509807

10.

Boehringer Ingelheim. Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis. 2025. Available from: https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/developing-novel-gene-therapy-cystic-fibrosis-patients [Last accessed: March 2, 2026].

11.

Masson

. Boehringer axes inhaled gene therapy after viewing cystic fibrosis data. Fierce Biotech; 2026. Available from: https://www.fiercebiotech.com/biotech/boehringer-axes-inhaled-gene-therapy-after-viewing-cystic-fibrosis-data [Last accessed: March 2, 2026].

12.

Ultragenyx Pharmaceutical. Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa). 2026. Available from: https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-announces-us-fda-acceptance-and-priority-review [Last accessed: March 2, 2026].

13.

Progeria Research Foundation and Forge Biologics. The Progeria Research Foundation and Forge Biologics Announce Manufacturing Partnership to Advance Gene Therapy for Children with Progeria. 2026. Available from: https://www.forgebiologics.com/the-progeria-research-foundation-and-forge-biologics-announce-manufacturing-partnership-to-advance-gene-therapy-for-children-with-progeria/ [Last accessed: March 3, 2026].